Literature DB >> 19584019

Delineating the psychic structure of substance abuse and addictions: should anxiety, mood and impulse-control dysregulation be included?

Pier Paolo Pani1, Icro Maremmani, Emanuela Trogu, Gian Luigi Gessa, Pedro Ruiz, Hagop Souren Akiskal.   

Abstract

Current "official" nosology (e.g. DSM IV) is largely limited to physical manifestations of addiction that can be objectively observed and are suited to the maintaining of an "atheoretical" perspective. However, addicted subjects display additional psychiatric symptoms that affect their well-being and social functioning and, in accordance with DSM IV, are typically relegated to the domain of psychiatric "comorbidity." We contend that the relationship of these psychiatric symptoms with addiction is very close, as demonstrated by the high frequency of association observed. We further assert that substance use may modify pre-existing psychic structures such as temperament and related subthreshold conditions and lead to addiction as a specific mental disorder, inclusive also of symptoms pertaining to mood/anxiety, or impulse-control dimensions. The present contribution addresses the weaknesses of the current DSM-based nosology of addiction-related mental comorbidity. We highlight the overlap of the biological substrates and the neurophysiology of addictive processes and psychiatric symptoms associated with addiction, and propose the inclusion of specific mood, anxiety, and impulse-control dimensions in the psychopathology of addictive processes. We postulate that addiction reaches beyond the mere result of drug-elicited effects on the brain and cannot be peremptorily equated only with the use of drugs despite the adverse consequences produced. We infer that mood, anxiety and impulse-control dysregulation is at the very core of both the origins and clinical manifestations of addiction and should be incorporated into the nosology of the same, emphasising how addiction is a relapsing chronic condition in which psychiatric manifestations play a crucial role. To conclude, addictionology cannot be severed from its psychopathological connotations, in view of the undeniable presence of symptoms, of their manifest contribution to the way addicted patients feel and behave, and to the role they play in maintaining the continued use of substances. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19584019     DOI: 10.1016/j.jad.2009.06.012

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  16 in total

Review 1.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

2.  French validation of the compulsive internet use scale (CIUS).

Authors:  Yasser Khazaal; Anne Chatton; Alessandra Horn; Sophia Achab; Gabriel Thorens; Daniele Zullino; Joël Billieux
Journal:  Psychiatr Q       Date:  2012-12

3.  Post-treatment drinking among HIV patients: Relationship to pre-treatment marijuana and cocaine use.

Authors:  Jennifer C Elliott; Efrat Aharonovich; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2015-03-21       Impact factor: 4.492

4.  Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).

Authors:  Icro Maremmani; Pier Paolo Pani; Matteo Pacini; Jacopo V Bizzarri; Emanuela Trogu; Angelo Gi Maremmani; Gilberto Gerra; Giulio Perugi; Liliana Dell'Osso
Journal:  Ann Gen Psychiatry       Date:  2010-04-13       Impact factor: 3.455

5.  Correlations between awareness of illness (insight) and history of addiction in heroin-addicted patients.

Authors:  Angelo Giovanni Icro Maremmani; Luca Rovai; Fabio Rugani; Matteo Pacini; Francesco Lamanna; Silvia Bacciardi; Giulio Perugi; Joseph Deltito; Liliana Dell'osso; Icro Maremmani
Journal:  Front Psychiatry       Date:  2012-07-09       Impact factor: 4.157

6.  Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?

Authors:  Angelo Giovanni Icro Maremmani; Luca Rovai; Pier Paolo Pani; Matteo Pacini; Francesco Lamanna; Fabio Rugani; Elisa Schiavi; Liliana Dell'osso; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2011-05-15       Impact factor: 3.455

7.  Comorbid Psychopathology and Alcohol Use Patterns among Methadone Maintenance Treatment Patients.

Authors:  Georgios Moussas; Irene Fanouraki; Argiro Pachi; Arezina Asomatou; Olga Drylli; Georgios Paschalakis; Athanasios Tselebis; Konstantinos Giotakis; Dionisios Bratis; Georgios Dermatis; Meni Malliori
Journal:  J Addict       Date:  2015-03-23

8.  Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment.

Authors:  Pier Paolo Pani; Emanuela Trogu; Federica Vigna-Taglianti; Federica Mathis; Roberto Diecidue; Ursula Kirchmayer; Laura Amato; Marina Davoli; Joli Ghibaudi; Antonella Camposeragna; Alessio Saponaro; Fabrizio Faggiano; Angelo Giovanni Icro Maremmani; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

9.  The impact of psychopathological subtypes on retention rate of patients with substance use disorder entering residential therapeutic community treatment.

Authors:  Angelo G I Maremmani; Pier Paolo Pani; Emanuela Trogu; Federica Vigna-Taglianti; Federica Mathis; Roberto Diecidue; Ursula Kirchmayer; Laura Amato; Joli Ghibaudi; Antonella Camposeragna; Alessio Saponaro; Marina Davoli; Fabrizio Faggiano; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2016-11-08       Impact factor: 3.455

10.  Psychopathology of addiction: May a SCL-90-based five dimensions structure be applied irrespectively of the involved drug?

Authors:  Pier Paolo Pani; Angelo G I Maremmani; Emanuela Trogu; Federica Vigna-Taglianti; Federica Mathis; Roberto Diecidue; Ursula Kirchmayer; Laura Amato; Joli Ghibaudi; Antonella Camposeragna; Alessio Saponaro; Marina Davoli; Fabrizio Faggiano; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2016-04-26       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.